DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Warfarin (Warfarin Sodium) - Published Studies

 
 



Warfarin Related Published Studies

Well-designed clinical trials related to Warfarin

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. [2015]

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. [2014]

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). [2014]

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. [2014]

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. [2014]

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. [2014]

Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. [2014]

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. [2014]

Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? [2013]

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. [2012]

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. [2011.11.15]

Apixaban versus warfarin in patients with atrial fibrillation. [2011.09.15]

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. [2011.09.08]

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. [2011.08.02]

[Effects of Ginkgo biloba extract on anticoagulation and blood drug level of warfarin in healthy wolunteers]. [2011.08]

Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. [2011.07]

Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects. [2011.06]

Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. [2011.06]

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. [2011.05.31]

Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. [2011.05.24]

Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. [2011.05]

Warfarin for refractory chronic cluster headache: a randomized pilot study. [2011.05]

Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. [2011.05]

Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. [2011.04]

Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. [2011.04]

Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. [2011.04]

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. [2011.03.10]

Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. [2011.03]

Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. [2011.02]

Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial. [2011.02]

Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. [2011.01.18]

Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. [2011.01]

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. [2011]

High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis. [2011]

Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. [2010.12]

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. [2010.12]

Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. [2010.12]

Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. [2010.11.30]

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). [2010.10]

Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. [2010.10]

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. [2010.09.18]

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. [2010.09]

Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. [2010.08.05]

Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. [2010.08]

EMPoWarMENT: Edmonton pediatric warfarin self-management pilot study in children with primarily cardiac disease. [2010.08]

Randomized clinical trial of a customized electronic alert requiring an affirmative response compared to a control group receiving a commercial passive CPOE alert: NSAID--warfarin co-prescribing as a test case. [2010.07]

Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin. [2010.05]

Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. [2010.05]

Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). [2010.04.15]

Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial. [2010.03]

Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. [2010.02.01]

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. [2010.01]

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. [2010]

Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy. [2010]

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. [2010]

Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). [2010]

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. [2010]

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. [2009.12.10]

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. [2009.12]

Thrice weekly warfarin administration in haemodialysis patients. [2009.10]

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. [2009.10]

Comparison of pain and ecchymosis with low-molecular-weight heparin vs. unfractionated heparin in patients requiring bridging anticoagulation after warfarin interruption: a randomized trial. [2009.10]

Dabigatran versus warfarin in patients with atrial fibrillation. [2009.09.17]

Use of Warfarin in People with Low Glomerular Filtration Rate or on Dialysis. [2009.09.09]

Practical application of the 10-mg warfarin initiation nomogram. [2009.09]

A re-appraisal of warfarin control in the treatment of deep vein thrombosis and / or pulmonary embolism. [2009.09]

Use of warfarin in people with low glomerular filtration rate or on dialysis. [2009.09]

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. [2009.08.15]

Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. [2009.08]

[The study of Chinese optimal anticoagulant range of warfarin for venous thromboembolism] [2009.07.07]

The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. [2009.07]

A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. [2009.07]

Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. [2009.05.01]

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. [2009.05]

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. [2009.05]

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. [2009.03.31]

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. [2009.03.03]

Prevention of venous thrombosis by warfarin after permanent transvenous leads implantation in high-risk patients. [2009.03]

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. [2009.03]

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. [2009.02.14]

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. [2009.01.27]

A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism. [2009.01.18]

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. [2008.12.01]

Warfarin prevents venous obstruction after cardiac devices implantation in high-risk patients: partial analysis. [2008.12]

Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. [2008.10]

Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. [2008.08]

Interaction between warfarin and Panax ginseng in ischemic stroke patients. [2008.07]

Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? [2008.06]

The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. [2008.06]

Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages. [2008.06]

Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. [2008.05]

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. [2008.03]

Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. [2008.03]

Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. [2008]

Less benefit from warfarin in diabetics after myocardial infarction? [2008]

The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon. [2008]

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. [2007.11.27]

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). [2007.11.01]

Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. [2007.11]

Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. [2007.11]

Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. [2007.10]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017